- Home
- AMED
AMED
Amedisys Inc
as 12-20-2024 4:00pm EST
Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, high acuity care segment, and personal care services. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States, Hospice segment operates many centers designed to provide comfort and support for terminally ill patients, Personal Care Segment provides individuals with assistance in their daily living activities and High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.
| Founded: | 1982 | Country: | United States |
| Employees: | N/A | City: | BATON ROUGE |
| Market Cap: | 2.9B | IPO Year: | N/A |
| Target Price: | $100.67 | AVG Volume (30 days): | 664.6K |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.52 | EPS Growth: | 3058.49 |
| 52 Week Low/High: | $82.17 - $98.95 | Next Earning Date: | 02-19-2025 |
| Revenue: | $2,321,060,000 | Revenue Growth: | 4.19% |
| Revenue Growth (this year): | 7.05% | Revenue Growth (next year): | 5.35% |
Latest Amedisys Inc News
AMED Breaking Stock News: Dive into AMED Ticker-Specific Updates for Smart Investing
Argus Research
4 days ago
AMED: What does Argus have to say about AMED?
Argus Research
11 days ago
AMED: Lowering target price to $90.00
Zacks
16 days ago
Amedisys (AMED) Down 12.4% Since Last Earnings Report: Can It Rebound?
Fox Business
17 days ago
DOJ launched probe into UnitedHealth for insider trading and attempted to stop monopoly
Argus Research
18 days ago
AMED: Lowering target price to $91.00
Argus Research
25 days ago
AMED: Raising target price to $96.00
Benzinga
a month ago
UnitedHealth's Optum Defends Multi-Billion Dollar Amedisys Deal, Ensures Competitive Landscape
Zacks
a month ago
DOJ Lawsuit Questions UnitedHealth's $3.3 Billion Amedisys Deal
Compare AMED vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AMED Amedisys Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.